

API Manufacturing

Headquartered in Ann Arbor, Michigan, Cayman Chemical Company has been supplying scientists worldwide with the resources necessary for advancing human and animal health since 1980. Cayman performs CGMP manufacturing for clients worldwide for use in human and veterinary medicine. We have over 40 years of experience in developing and manufacturing APIs, and extensive proficiencies in performing multi-step organic syntheses. Our CGMP facilities have a proven track record of strict adherence to regulatory guidelines and requirements, and they are routinely audited by government, pharmaceutical, and independent third parties.



Facilities Overview

- EMA and US FDA-certified and registered
- 480 employees worldwide
- Manufacturer of APIs and impurities reference standards
- 30-40 kg annual manufacturing capacity (with scale-up capabilities)
- APIs developed using non-infringing routes of synthesis (statements available upon request)
- ISO 9001, ISO 14001, ISO 45001 certified (Cayman Pharma)
- DEA licensed for manufacturing, analysis, and export (Cayman Chemical)

Commercial API Production

We manufacture prostaglandin APIs for commercial distribution in ophthalmologic, vascular, and animal health applications. Cayman is proud to be one of the first CDMOs offering psychedelic compounds for use in human clinical trials investigating their utility in neuropsychiatric disorders.

- CGMP Latanoprost (CEP granted) 
- CGMP Bimatoprost
- CGMP Latanoprostene Bunod
- CGMP Tafluprost
- CGMP Travoprost
- CGMP Epoprostenol sodium salt
- CGMP (+)-Cloprostenol sodium salt
- CGMP (±)-Cloprostenol sodium salt
- CGMP Psilocin*
- CGMP Psilocybin*

* Appropriate for human clinical trials

Development API Production

- 3,4-MDMA
- N,N-DMT